Antihistamine use and risk of ovarian cancer: A population-based case-control study

Freija Verdoodt, Anton Pottegård, Christian Dehlendorff, Marja Jäättelä, Jesper Hallas, Søren Friis, Susanne K. Kjaer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Objective: Histamine is suggested to play a role in ovarian carcinogenesis. We examined the association between antihistamine use and ovarian cancer risk in a nationwide case-control study. Study design: Cases (n = 5 556) comprised all women in Denmark aged 30–84 years with a histologically verified first diagnosis of epithelial ovarian cancer during 2000-2015. Age-matched population controls (n = 83 340) were selected using risk-set sampling. Data on prescription use, patient and demographic characteristics were retrieved from nationwide registries. Main outcome measures: We used conditional logistic regression to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for epithelial ovarian cancer associated with antihistamine use (≥2 prescriptions). The association was evaluated according to patterns of antihistamine use, menopausal status, and histological subtype of ovarian cancer. Results: Ever use of antihistamines was not associated with ovarian cancer overall (OR = 0.97, 95% CI = 0.90–1.05). The lack of association remained in subanalyses for patterns of antihistamine use. We observed an inverse association between antihistamine use and ovarian cancer among pre-menopausal women (<50 year: OR = 0.72, 95% CI = 0.57-0.90), but not post-menopausal women (≥50 year: OR = 1.02, 95%CI = 0.93–1.11). In analyses of histological subtypes, an inverse association emerged for mucinous ovarian cancer (OR = 0.74, 95% CI = 0.57-0.96), but not for other subtypes. Conclusion: Antihistamine use was not associated with overall ovarian cancer risk. Additional research is needed to confirm inverse associations between antihistamine use and mucinous ovarian cancer, and overall ovarian cancer among pre-menopausal women.

SprogEngelsk
TidsskriftMaturitas
Vol/bind120
Sider47-52
ISSN0378-5122
DOI
StatusUdgivet - 1 feb. 2019

Fingeraftryk

Histamine Antagonists
Ovarian Neoplasms
Case-Control Studies
Odds Ratio
Population
Confidence Intervals
Prescriptions
Population Control
Denmark
Histamine
Registries
Logistics
Logistic Models
Outcome Assessment (Health Care)
Sampling
Research

Emneord

    Citer dette

    Verdoodt, Freija ; Pottegård, Anton ; Dehlendorff, Christian ; Jäättelä, Marja ; Hallas, Jesper ; Friis, Søren ; Kjaer, Susanne K. / Antihistamine use and risk of ovarian cancer : A population-based case-control study. I: Maturitas. 2019 ; Bind 120. s. 47-52.
    @article{d4ffde528341405bb0aaeb6e4cea7fd8,
    title = "Antihistamine use and risk of ovarian cancer: A population-based case-control study",
    abstract = "Objective: Histamine is suggested to play a role in ovarian carcinogenesis. We examined the association between antihistamine use and ovarian cancer risk in a nationwide case-control study. Study design: Cases (n = 5 556) comprised all women in Denmark aged 30–84 years with a histologically verified first diagnosis of epithelial ovarian cancer during 2000-2015. Age-matched population controls (n = 83 340) were selected using risk-set sampling. Data on prescription use, patient and demographic characteristics were retrieved from nationwide registries. Main outcome measures: We used conditional logistic regression to estimate odds ratios (ORs) with 95{\%} confidence intervals (CIs) for epithelial ovarian cancer associated with antihistamine use (≥2 prescriptions). The association was evaluated according to patterns of antihistamine use, menopausal status, and histological subtype of ovarian cancer. Results: Ever use of antihistamines was not associated with ovarian cancer overall (OR = 0.97, 95{\%} CI = 0.90–1.05). The lack of association remained in subanalyses for patterns of antihistamine use. We observed an inverse association between antihistamine use and ovarian cancer among pre-menopausal women (<50 year: OR = 0.72, 95{\%} CI = 0.57-0.90), but not post-menopausal women (≥50 year: OR = 1.02, 95{\%}CI = 0.93–1.11). In analyses of histological subtypes, an inverse association emerged for mucinous ovarian cancer (OR = 0.74, 95{\%} CI = 0.57-0.96), but not for other subtypes. Conclusion: Antihistamine use was not associated with overall ovarian cancer risk. Additional research is needed to confirm inverse associations between antihistamine use and mucinous ovarian cancer, and overall ovarian cancer among pre-menopausal women.",
    keywords = "Antihistamines, Cancer prevention, Case-control study, Menopause, Ovarian neoplasms, Pharmacoepidemiology",
    author = "Freija Verdoodt and Anton Potteg{\aa}rd and Christian Dehlendorff and Marja J{\"a}{\"a}ttel{\"a} and Jesper Hallas and S{\o}ren Friis and Kjaer, {Susanne K.}",
    year = "2019",
    month = "2",
    day = "1",
    doi = "10.1016/j.maturitas.2018.11.014",
    language = "English",
    volume = "120",
    pages = "47--52",
    journal = "Maturitas",
    issn = "0378-5122",
    publisher = "Elsevier",

    }

    Antihistamine use and risk of ovarian cancer : A population-based case-control study. / Verdoodt, Freija; Pottegård, Anton; Dehlendorff, Christian; Jäättelä, Marja; Hallas, Jesper; Friis, Søren; Kjaer, Susanne K.

    I: Maturitas, Bind 120, 01.02.2019, s. 47-52.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

    TY - JOUR

    T1 - Antihistamine use and risk of ovarian cancer

    T2 - Maturitas

    AU - Verdoodt, Freija

    AU - Pottegård, Anton

    AU - Dehlendorff, Christian

    AU - Jäättelä, Marja

    AU - Hallas, Jesper

    AU - Friis, Søren

    AU - Kjaer, Susanne K.

    PY - 2019/2/1

    Y1 - 2019/2/1

    N2 - Objective: Histamine is suggested to play a role in ovarian carcinogenesis. We examined the association between antihistamine use and ovarian cancer risk in a nationwide case-control study. Study design: Cases (n = 5 556) comprised all women in Denmark aged 30–84 years with a histologically verified first diagnosis of epithelial ovarian cancer during 2000-2015. Age-matched population controls (n = 83 340) were selected using risk-set sampling. Data on prescription use, patient and demographic characteristics were retrieved from nationwide registries. Main outcome measures: We used conditional logistic regression to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for epithelial ovarian cancer associated with antihistamine use (≥2 prescriptions). The association was evaluated according to patterns of antihistamine use, menopausal status, and histological subtype of ovarian cancer. Results: Ever use of antihistamines was not associated with ovarian cancer overall (OR = 0.97, 95% CI = 0.90–1.05). The lack of association remained in subanalyses for patterns of antihistamine use. We observed an inverse association between antihistamine use and ovarian cancer among pre-menopausal women (<50 year: OR = 0.72, 95% CI = 0.57-0.90), but not post-menopausal women (≥50 year: OR = 1.02, 95%CI = 0.93–1.11). In analyses of histological subtypes, an inverse association emerged for mucinous ovarian cancer (OR = 0.74, 95% CI = 0.57-0.96), but not for other subtypes. Conclusion: Antihistamine use was not associated with overall ovarian cancer risk. Additional research is needed to confirm inverse associations between antihistamine use and mucinous ovarian cancer, and overall ovarian cancer among pre-menopausal women.

    AB - Objective: Histamine is suggested to play a role in ovarian carcinogenesis. We examined the association between antihistamine use and ovarian cancer risk in a nationwide case-control study. Study design: Cases (n = 5 556) comprised all women in Denmark aged 30–84 years with a histologically verified first diagnosis of epithelial ovarian cancer during 2000-2015. Age-matched population controls (n = 83 340) were selected using risk-set sampling. Data on prescription use, patient and demographic characteristics were retrieved from nationwide registries. Main outcome measures: We used conditional logistic regression to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for epithelial ovarian cancer associated with antihistamine use (≥2 prescriptions). The association was evaluated according to patterns of antihistamine use, menopausal status, and histological subtype of ovarian cancer. Results: Ever use of antihistamines was not associated with ovarian cancer overall (OR = 0.97, 95% CI = 0.90–1.05). The lack of association remained in subanalyses for patterns of antihistamine use. We observed an inverse association between antihistamine use and ovarian cancer among pre-menopausal women (<50 year: OR = 0.72, 95% CI = 0.57-0.90), but not post-menopausal women (≥50 year: OR = 1.02, 95%CI = 0.93–1.11). In analyses of histological subtypes, an inverse association emerged for mucinous ovarian cancer (OR = 0.74, 95% CI = 0.57-0.96), but not for other subtypes. Conclusion: Antihistamine use was not associated with overall ovarian cancer risk. Additional research is needed to confirm inverse associations between antihistamine use and mucinous ovarian cancer, and overall ovarian cancer among pre-menopausal women.

    KW - Antihistamines

    KW - Cancer prevention

    KW - Case-control study

    KW - Menopause

    KW - Ovarian neoplasms

    KW - Pharmacoepidemiology

    U2 - 10.1016/j.maturitas.2018.11.014

    DO - 10.1016/j.maturitas.2018.11.014

    M3 - Journal article

    VL - 120

    SP - 47

    EP - 52

    JO - Maturitas

    JF - Maturitas

    SN - 0378-5122

    ER -